📊 REPL Key Takeaways
Is Replimune Group, Inc. (REPL) a Good Investment?
Replimune is a pre-revenue biotech company with no commercialized products, posting $246.6M in operating losses and burning $228.4M in free cash flow annually. Despite a solid cash position of $123M and conservative leverage (0.23x D/E), the burn rate implies only 6-7 months of runway at current spending levels, necessitating immediate capital raises or dramatic operational changes to avoid liquidity crisis.
Replimune remains pre‑revenue with very large operating losses and deeply negative returns on assets and equity, indicating no current path to profitability. While liquidity and leverage are acceptable today, the magnitude of cash burn relative to cash on hand implies a short runway and a high likelihood of near‑term dilutive financing absent revenue initiation or significant cost reduction.
Why Buy Replimune Group, Inc. Stock? REPL Key Strengths
- Strong cash position of $123.0M provides near-term operational runway
- Conservative leverage with 0.23x debt-to-equity ratio and low absolute debt of $47.6M
- Excellent liquidity ratios (5.60x current/quick ratio) indicate ability to meet short-term obligations
- Significant insider activity (16 Form 4 filings in 90 days) suggests management confidence in pipeline
- Strong liquidity with 5.6x current ratio and $123M cash
- Moderate leverage (0.23x D/E) with manageable long‑term debt
- Low capital intensity (capex ~$4M) provides operating flexibility
REPL Stock Risks: Replimune Group, Inc. Investment Risks
- Pre-revenue company with zero sales indicates no validated commercial products
- Massive annual cash burn of $228.4M (free cash flow) against only $123M cash on hand
- Operating losses of $246.6M with negative ROE (-114.3%) and ROA (-72.2%) demonstrate unprofitable operations
- Only 6-7 months of cash runway at current burn rate; requires external financing or operational pivot
- High clinical/regulatory execution risk typical of early-stage biotech with no approved products
- Sustained zero revenue and heavy operating losses (-$247M) and FCF (-$228M)
- Short cash runway relative to burn, elevating dilution/financing risk
- Negative ROE/ROA and interest coverage (-55.7x) signal weak profitability profile
Key Metrics to Watch
- Cash burn rate and remaining runway (critical for survival)
- Clinical trial progress and FDA regulatory milestones for pipeline programs
- Cash position and capital raise announcements or dilution
- Operating expense trends and whether burn rate can be reduced
- Operating cash flow (quarterly burn)
- Operating expenses trend (R&D + SG&A)
Replimune Group, Inc. (REPL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.60x current ratio provides a solid financial cushion.
REPL Profit Margin, ROE & Profitability Analysis
REPL vs Healthcare Sector: How Replimune Group, Inc. Compares
How Replimune Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Replimune Group, Inc. Stock Overvalued? REPL Valuation Analysis 2026
Based on fundamental analysis, Replimune Group, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Replimune Group, Inc. Balance Sheet: REPL Debt, Cash & Liquidity
REPL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Replimune Group, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.24 indicates the company is currently unprofitable.
REPL Revenue Growth, EPS Growth & YoY Performance
REPL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2018 | N/A | -$4.2M | N/A |
| Q2 2018 | N/A | -$4.0M | N/A |
| Q1 2018 | N/A | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Replimune Group, Inc. Dividends, Buybacks & Capital Allocation
REPL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Replimune Group, Inc. (CIK: 0001737953)
📋 Recent SEC Filings
❓ Frequently Asked Questions about REPL
What is the AI rating for REPL?
Replimune Group, Inc. (REPL) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are REPL's key strengths?
Claude: Strong cash position of $123.0M provides near-term operational runway. Conservative leverage with 0.23x debt-to-equity ratio and low absolute debt of $47.6M. ChatGPT: Strong liquidity with 5.6x current ratio and $123M cash. Moderate leverage (0.23x D/E) with manageable long‑term debt.
What are the risks of investing in REPL?
Claude: Pre-revenue company with zero sales indicates no validated commercial products. Massive annual cash burn of $228.4M (free cash flow) against only $123M cash on hand. ChatGPT: Sustained zero revenue and heavy operating losses (-$247M) and FCF (-$228M). Short cash runway relative to burn, elevating dilution/financing risk.
What is REPL's revenue and growth?
Replimune Group, Inc. reported revenue of $0.0.
Does REPL pay dividends?
Replimune Group, Inc. does not currently pay dividends.
Where can I find REPL SEC filings?
Official SEC filings for Replimune Group, Inc. (CIK: 0001737953) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is REPL's EPS?
Replimune Group, Inc. has a diluted EPS of $-2.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is REPL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Replimune Group, Inc. has a STRONG SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is REPL stock overvalued or undervalued?
Valuation metrics for REPL: ROE of -114.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy REPL stock in 2026?
Our dual AI analysis gives Replimune Group, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is REPL's free cash flow?
Replimune Group, Inc.'s operating cash flow is $-224.2M, with capital expenditures of $4.2M.
How does REPL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -114.3% (avg: 15%), current ratio 5.60 (avg: 2).